Among 1,000 selected compounds and antibiotics tested against all or portions of the tumor spectrum (33 tumors), cytoxan was the most effective, having a marked inhibitory to complete inhibitory effect on 26 out of 33 tumors.
Cytoxan (50 mg/kg/day for mice; 25 mg/kg/day for rats) had a destructive effect on well established 7-day-old Sarcoma T241, Carcinoma 1025, Lewis bladder carcinoma, Wagner and Ridgway osteogenic sarcomas, Mecca lymphosarcoma, and Leukemia L 4946 in mice; and Flexner-Jobling carcinoma, Walker carcinosarcoma 256, Jensen sarcoma, Iglesias sarcoma, Moore sarcoma No. 1, and Murphy-Sturm lymphosarcoma in rats.
Repeated intraperitoneal injections of cytoxan had a moderate inhibitory effect on spontaneous mammary adenocarcinomas in mice and a slight inhibitory effect on well established sarcomas induced by methylcholanthrene in mice, but there was no complete tumor regression.
This investigation was supported by a grant from the American Cancer Society and by a Contract SA-43-ph-2445, National Institutes of Health, Cancer Chemotherapy National Service Center.